This study serves as a follow-up to a March 2012 analysis conducted by Frank Sasinowski that reviewed the quantum of effectiveness evidence that is required to secure FDA approval of therapies for rare diseases, or orphan drugs, from the 1983 enactment of the Orphan Drug Act through June 30, 2010. The current study was designed to determine, over the 4 years since the original study, how frequently FDA has required marketing applications of drugs for rare diseases to provide the conventional level of proof of effectiveness that is ordinarily expected for most drugs for prevalent diseases.
Methods:
This study employed methods similar to the original analysis, identifying the noncancer orphan drugs approved as new chemical entities by relying on FDA’s publicly available documents for drugs approved by FDA from July 1, 2010, to June 30, 2014. These materials were used to identify the basis for each drug’s approval, and each approval was analyzed and classified.
Results:
The results of this study show that for just over two-thirds of all noncancer orphan drugs approved between July 1, 2010, and June 30, 2014, FDA did not require the orphan drug applications to provide the conventional level of proof of effectiveness that is ordinarily expected for drugs for prevalent diseases. This is consistent with the results of the 2012 analysis.
Conclusions:
The findings further support that FDA has demonstrated extraordinarily reasonable flexibility in its review of certain applications for orphan drugs and reinforce the need for FDA and drug companies to better understand and discuss the various types of flexibility.
Federal Food, Drug, and Cosmetic Act§ 526(d), 21 USC 360bb(d) (1985).
3.
Orphan Drug Act. Pub. L. No. 97-414, 96 Stat. 2049 (1983).
4.
Federal Food, Drug, and Cosmetic Act§ 505(d), 21 USC 355(d) (1962).
5.
SasinowskiFJ. Quantum of effectiveness evidence in FDA’s approval of orphan drugs: cataloging FDA’s flexibility in regulating therapies for persons with rare disorders. Drug Information Journal. 2012;46(2):238–263. http://www.rarediseases.org/docs/policy/NORDstudyofFDAapprovaloforphandrugs.pdf. Accessed November 10, 2014.
6.
WoodcockJ. The future of orphan drug development. Nature. 2012;92(2):146–148.
7.
National Human Genome Research Institute, National Institutes of Health. Frequently asked questions about rare diseases. http://www.genome.gov/27531963. Accessed November 24, 2014.
8.
Federal Food, Drug, and Cosmetic Act§ 505(d), 21 USC 9 (1962).
US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products. Rockville, MD: Center for Drug Evaluation and Research; 1998.
11.
Food and Drug Administration Modernization Act of 1997§115, 21 USC 355 (2014).
12.
21 CFR Part 314, Subpart H—accelerated approval of new drugs for serious and life-threatening illnesses. Fed Regist. 1992;57(239):58942–58960.
13.
Food and Drug Administration Safety and Innovation Act of 2012§ 901, 21 USC 356 (2012).
14.
US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics. Rockville, MD: Center for Drug Evaluation and Research; 2014.
EganA.Center for Drug Evaluation and Research, US Food and Drug Administration: office director memo for Elosulfase alfa (vimizim) [decisional memo]. February14, 2014.
19.
MulbergA. Drug development in rare and orphan diseases: efficacy endpoint and clinical outcome assessment considerations in registration trials [PowerPoint presentation]. Vimizim (elosulfase alfa) Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Silver Spring, MD, November19, 2013.
21 CFR Part 314.600 and 21 CFR Part 601.90—approval of new drugs when human efficacy studies are not ethical or feasible. Fed Regist. 2002;67(105):37988–37998.
ValiB. US Food and Drug Administration, Center for Drug Evaluation and Research: statistical review for taliglucerase alfa (Elelyso). PublishedMay2, 2012.
President’s Council of Advisors on Science and Technology. Report to the president on propelling innovation in drug discovery, development, and evaluation. Washington, DC: Executive Office of the President, President’s Council of Advisors on Science and Technology. http://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-fda-final.pdf. Published2012. Accessed November 10, 2014.
